Advocacy Actions
Meeting with the Department of Pharmaceutical Pricing and Bidding and Procurement, National Healthcare Security Administration (NHSA)
On 10th July, Vice Chairs of the Pharmaceutical Working Group met with officials from the Department of Pharmaceutical Pricing and Bidding and Procurement of the National Healthcare Security Administration (NHSA).
Read moreCall for Comments on the Measures for the Administration of Advertisement Review of Drugs, Medical Devices, Health Food and Food for Special Medical Purposes (Draft)
On 28th June, the Agriculture, Food and Beverage Working Group, the FSMP Advisory Committe (Sub-working Group), Healthcare Equipment Working Group and Pharmaceutical Working Group submitted comments to the State Administration for Market Regulation on the Measures for the Administration of Advertisement Review of Drugs, Medical Devices, Health Food and Food for Special Medical Purposes (Draft).
Read moreComments to the National Medical Products Administration (NMPA) on the Circular on Tightening the Regulation of Marketing Authorisation Holders for Entrusted Production of Drugs
On 23rd June, European Chamber Pharmaceutical Working Group submitted comments to the National Medical Products Administration (NMPA) on the Circular on Tightening the Regulation of Marketing Authorisation Holders for Entrusted Production of Drugs.
Read moreComments to the National Healthcare Security Administration (NHSA) on 2023 National Reimbursement Drug List (NRDL) Adjustment Workplan
On 15th June, European Chamber Pharmaceutical Working Group submitted comments to the National Healthcare Security Administration (NHSA) on the 2023 National Reimbursement Drug List (NRDL) Adjustment Workplan.
Read moreMeeting with the Development and Research Centre (DRC) of the State Council on Healthcare Industry
Meeting with the Development and Research Centre of the State Council on Healthcare Industry
Read moreComments to National Medical Products Administration (NMPA) on the Administrative Measures for Drug Standards (Draft for comment)
European Chamber Pharmaceutical Working Group submitted comments to National Medical Products Administration (NMPA) on the Administrative Measures for Drug Standards (Draft for Comment), on 13th January 2023.
Read moreComments to State Administration for Market Regulation (SAMR) on the Anti-unfair Competition Law (Revised draft for comments)
European Chamber submitted comments to State Adminstration for Market Regulation (SAMR) on the Anti-unfair Competition Law of the People's Republic of China (Revised Draft for Comment), on 21st December 2022.
Read moreComments to China National Intellectual Property Administration (CNIPA) on the Patent Examination Guidelines (Revised draft for comment)
On 15th December, European Chamber IPR Working Group submitted comments to China National Intellectual Property Administration (CNIPA) on the Patent Examination Guidelines (Revised draft for comments).
Read moreComments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (Draft for Comments)
On 9th December, European Chamber Pharmaceutical Working Group submitted comments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (Draft for Comments).
Read moreEuropean Chamber Co-organises EU-China Biopharmaceutical Innovation and Development Roundtable
On 24th November 2022, the EU-China Biopharmaceutical Innovation and Development Roundtable took place using a hybrid format connecting Beijing and Brussels.
The roundtable, co-organised by the European Chamber and the China Society for Drug Regulation (CSDR), with the support from the European Federation of Pharmaceutical Industries and Associations (EFPIA), enabled an open dialogue on pro-innovation regulatory policies between representatives from the European pharmaceutical industry and the National Medical Products Administration (NMPA).